A pre-column derivatization method allowing quantitative metabolite profiling of carboxyl and phenolic hydroxyl group containing pharmaceuticals in human plasma via liquid chromatography-inductively coupled plasma-tandem mass spectrometry (LC-ICP-MS/MS) by Li, Sanwang et al.
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The development of suitable analytical methods for drug ADME (absorption, distribution, metabolism and
excretion) studies is of great importance. The currently routinely applied detection techniques usually
demonstrate a structure-dependent analytical response (MS-based method) or require the synthesis of
a radiolabelled version of the parent drug (radiodetection) for accurate quantiﬁcation. Inductively
coupled plasma-(tandem) mass spectrometry (ICP-MS(/MS)) oﬀers a promising alternative to
radiolabelling followed by radiodetection due to the structure-independent nature of its analytical
response. Within the context of this study, an accurate, simple and sensitive HPLC-ICP-MS/MS method
for the quantitative metabolite proﬁling of diclofenac in human plasma based on the pre-column
derivatization of the carboxylic and phenolic –OH groups present in the parent drug and its major
metabolite, 40-hydroxy-diclofenac, was developed and validated. A cost-eﬀective and commercially
available derivatization reagent, p-bromophenacyl bromide (p-BPB), was applied for the introduction of
Br into the drug molecule and its major metabolite, enabling the element-selective detection and
quantiﬁcation based on the Br-signal. The presence of Cl in both diclofenac and 40-hydroxy-diclofenac
allowed an additional validation via simultaneous monitoring of the Cl-signal by using a state-of-art ICP-
MS/MS instrument equipped with a collision/reaction cell. The reaction conditions were successfully
optimized to achieve a quantitative formation of the corresponding derivatization products, while the
baseline separation of the target compounds in a typical biological matrix (i.e. human plasma) was
achieved using gradient reversed phase high-performance liquid chromatography (RP-HPLC). A ﬁt-for-
purpose accuracy (recovery between 85–115%) and precision (repeatability #7.2% RSD) were achieved.
The limits of quantiﬁcation (LOQ) are z50 mg L1 for Br and z80 mg L1 for Cl, corresponding to
z0.2 mg L1 andz0.4 mg L1 of diclofenac, respectively.Introduction
The investigation of drug ADME (absorption, distribution,
metabolism and excretion) behavior is an inevitable part of drug
development.1,2 Currently, a variety of techniques are used for, Atomic and Mass Spectrometry Research
281-S12, 9000 Ghent, Belgium. E-mail:
, Janssen R&D, Turnhoutseweg 30, 2340
nd Macromolecular Chemistry, Campus
elgium
tion (ESI) available. See DOI:
74–282the identication and quantication of drug metabolites, such
as (ultra)high-performance liquid chromatography coupled to
(tandem) mass spectrometry ((U)HPLC-MS(/MS)),3–7 nuclear
magnetic resonance (NMR) spectroscopy8–10 etc. As is well
known, these traditional techniques demonstrate either
a structure-dependent analytical response (MS-based tech-
niques), requiring analytical standards for all of the metabolites
for accurate quantication, or are hindered by a lack of suﬃ-
cient selectivity and/or sensitivity (e.g. NMR). As individual
analytical standards are typically not available for (all of) the
metabolites, especially in the early phase of drug develop-
ment,11 an analytical approach with structure-independent
response is necessary for quantitative drug metabolite
proling. The present standard methodology is based onThis journal is © The Royal Society of Chemistry 2018
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View Article Onlineradiolabelling followed by radiodetection aer chromato-
graphic separation.12–15 While this technique permits
a straightforward quantication of the drug-related compounds
based on the decay of the radionuclide (14C,3H), it also has
obvious drawbacks, such as the need for the synthesis of
a radiolabelled version of the parent drug, which is oen time-
consuming and expensive, and the ethical issues related to the
administration of radioactive materials to humans and
animals.12,14,16 Therefore, the development of novel, alternative
strategies for quantitative drug metabolite proling is still
highly desirable in the pharmaceutical sciences especially in the
drug discovery and early development phase during which
a radiolabelled version of the drug is typically not available yet.
Over the past decade, the application of HPLC-ICP-MS for
drug metabolite proling has gained a lot of attention.2,17 While
eliminating the major disadvantages of radiolabelling, ICP-MS
oﬀers excellent detection sensitivity, high selectivity, a struc-
ture-independent response and a wide linear dynamic range
making it a promising alternative to radiodetection. The
potentials of the technique have been recently highlighted by
several studies for the metabolite proling of metal- and
heteroelement-containing drugs.12,16,18–22 However, the wide and
routine application of HPLC-ICP-MS in pharmaceutical R&D is
seriously hindered by the fact that most of the drugs do not
contain any ICP-MS detectable element, therefore the develop-
ment of reliable and quantitative derivatization strategies tar-
geting the functional groups typically present in drug
molecules23 can signicantly expand the application area of
ICP-MS inmetabolite proling and pharmaceutical analysis. On
some occasions, the introduction of an ICP-MS detectable
hetero-element by utilizing the chemical reactivity of the
compounds of interest could be used as an eﬀective strategy to
enable the application of HPLC-ICP-MS for this purpose.24–28
Aer a rst successful attempt aiming at the quantitative
metabolite proling of an amino group containing pharma-
ceutical in human plasma via the development and validation
of a novel pre-column derivatization approach followed by
HPLC-ICP-MS determination,28 the development of novel
derivatization strategies and their application for HPLC-ICP-MS
was extended to other common functional groups i.e. carboxyl
(–COOH) and phenolic OH groups in this study. Although the
derivatization of these groups can be accomplished by using
a variety of reagents, only a few have been reported in the
literature for HPLC-ICP-MS analysis so far.29,30 A phosphorus-
containing reagent, tris(2,4,6-trimethoxyphenyl)phosphonium
propylamine (TMPP) bromide was used by Cartwright et al.
for the determination of small molecule carboxylic acids using
RP-HPLC coupled with sector eld ICP-MS.29 The derivatization
was carried out aer activating the carboxyl groups with chloro-
1-methylpyridinium iodide (CMPI) and triethylamine (TEA).
The introduction of P allowed 31P+-selective detection for the
quantication of the acids normally not accessible to ICP-MS
detection. The disadvantages of the method are the insuﬃ-
cient reaction eﬃciency and relatively poor sensitivity as
a consequence of the relatively low ionization eﬃciency of P, the
quantication of which is further compromised by the occur-
rence of strong spectral interference.31,32 Marshall et al.This journal is © The Royal Society of Chemistry 2018developed a capillary HPLC-ICP-MS method for the determi-
nation of carboxylic acids via derivatization with N-(2-amino-
ethyl)ferrocenecarboxamide.30 Carboxyl groups were activated
by CMPI/TEA prior to the derivatization, similarly to the study
mentioned previously. The introduction of a ferrocene group
not only signicantly improved the ICP-MS detection sensitivity
of the target analytes based on selective Fe detection, but also
facilitated their separation with reversed-phase chromatog-
raphy by increasing the hydrophobicity of the derivatives.
Although Fe is a more preferable element for ICP-MS detection
than, e.g., P, or other non-metallic hetero-elements, its appli-
cation can be considered rather unfortunate due to the stainless
steel parts of (U)HPLC systems on the one hand and the spectral
interference from 40Ar16O+ at m/z ¼ 56 on the other,33,34 neces-
sitating the use of higher mass resolution, chemical resolution
or aerosol desolvation.
p-Bromophenacyl bromide (p-BPB) is known as an eﬀective,
aﬀordable and commercially available alkylating agent for the
derivatization of carboxylic acids aiming at the enhancement of
their UV-absorption.35 Besides the improved UV-detection, the
introduction of bromine also enables straightforward ICP-MS
determination of the derivatized analytes.
Within the context of this study, the successful application of
p-bromophenacyl bromide (p-BPB) as a derivatization reagent
was demonstrated for the quantitative metabolite proling of
diclofenac in human plasma using RP-HPLC for separation of
the target compounds and ICP-MS/MS for Br detection. Taking
advantage of the Cl-content of both diclofenac and its major
metabolite (40-hydroxy-diclofenac), an additional validation
based on Cl detection could also be achieved by using a state-of-
art ICP-MS/MS system with H2 as a reaction gas in its octopole
collision/reaction cell, as recently published by our group.36,37
Experimental section
Materials and reagents
Diclofenac sodium (pharmaceutical secondary standard with
a purity of 99.9%), 40-hydroxy-diclofenac (analytical standard
with a purity $98%) and p-bromophenacyl bromide (p-BPB,
$99.0%) were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Acetonitrile (LC-MS grade) was obtained from VWR
International (Leuven, Belgium). Acetone (ACS reagent,
$99.5%), triuoroacetic acid (TFA, $99.0%, eluent additive for
LC-MS), formic acid ($88.0%, TraceSELECT®), acetic acid
($99.0%, TraceSELECT®), triethylamine (TEA, $99%) and
ammonium acetate ($99.9995%, TraceSELECT®) were also
purchased from Sigma-Aldrich. Ammonium bromide (1000  5
mg mL1 for Br) element stock solution was purchased from
Inorganic Ventures (Christiansburg, VA, USA). Ultrapure grade
water (resistivity $ 18.2 MU cm) was produced in-house in
a Millipore Direct-Q water purication system (Millipore, Bill-
erica, MA, USA).
Preparation of standard and reagent working solutions. The
stock solution of diclofenac sodium at a concentration of 0.9 mg
mL1 was prepared in acetone and stored at 4 C. The 40-
hydroxy-diclofenac stock solution was prepared in acetonitrile
at a concentration of 2.2 mg mL1 and stored at 20 C. A TEAJ. Anal. At. Spectrom., 2018, 33, 274–282 | 275
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View Article Onlineworking solution was prepared by diluting 28 mL of TEA with
10 mL of acetonitrile to obtain a concentration of 20 mM.
40 mM p-BPB working solution was prepared by dissolving
110 mg of p-BPB in 10 mL of acetonitrile. The calibration
standard solutions (STD) containing both Br and Cl and applied
for the quantication of the derivatives were prepared by
appropriate dilution of the diclofenac sodium stock solution
and ammonium bromide element stock solution in 75% (v/v)
acetonitrile in MQ water (containing 0.05% (v/v) TFA) in
a concentration range of 0.1–6 mg L1 Cl and Br, respectively.
Samples and sample preparation. Blank human plasma was
collected from healthy individuals not subject to any medical
treatment and stored at 20 C until analysis. A similar sample
preparation procedure was followed as recently published by Li
et al.28 Briey, 900 mL of acetonitrile was added to 300 mL of
plasma in a 15 mL centrifuge tube (VWR International, Leuven,
Belgium) to precipitate the plasma proteins. The mixture was
then thoroughly vortexed for 1 min and centrifuged at 4400 rpm
for 20 minutes. Aer that, 1100 mL of supernatant was pipetted
into a 5 mL borosilicate glass tube (VWR International, Leuven,
Belgium) and evaporated to dryness in a vacuum chamber. The
residue was reconstituted with 100 mL of acetonitrile under
ultrasonication (10 min).
Derivatization procedure. The chemical reaction for the
derivatization of diclofenac and 40-hydroxy-diclofenac with p-
BPB is demonstrated in Fig. 1. The derivatization was carried
out as follows: 100 mL of TEA solution (20 mM in acetonitrile)
and subsequently 100 mL of p-BPB solution (40 mM in aceto-
nitrile) were added to 100 mL of the reconstituted plasma
sample solution in a 5 mL borosilicate glass tube. Aer vortex-
ing for 30 s, the reaction mixture was incubated at 80 C for 45
minutes. Prior to injection into the HPLC-ICP-MS/MS system,
the derivatization solution was cooled to room temperature and
admixed with 300 mL of 1% (v/v) TFA solution (in MQ water) to
adjust the pH and decrease the organic content for achieving
optimal chromatographic performance.
Instrumentation
HPLC-UV. For the optimization of reaction conditions,
a simple and fast HPLC-UV method was applied for the simul-
taneous determination of 40-hydroxy-diclofenac, diclofenac and
their derivatives. The chromatographic separation was carriedFig. 1 Reaction for the derivatization of diclofenac and 40-hydroxy-
diclofenac with p-BPB.
276 | J. Anal. At. Spectrom., 2018, 33, 274–282out on a Waters SunFire C18 column (4.6  150 mm, 3.5 mm) by
using an Agilent 1260 Innity HPLC system (Agilent Technolo-
gies, Waldbronn, Germany) equipped with an Agilent 1260
Innity binary pump, an Agilent 1260 Innity vacuum degasser,
an Agilent 1260 Innity auto sampler, an Agilent 1290 Innity
thermostated column compartment and an Agilent 1260
Innity Multiple Wavelength detector. The eluent system con-
sisted of 0.05% (v/v) TFA inMQwater as eluent A and 0.05% (v/v)
TFA in acetonitrile as eluent B. The gradient elution program
was optimized as follows: 0–4min: 45% eluent A (55% eluent B),
4–4.01 min: 45 / 35% eluent A (55 / 65% eluent B), 4.01–
8 min: 35% eluent A (65% eluent B), 8–8.01 min: 35 / 0%
eluent A (65/ 100% eluent B), 8.01–11 min: 100% eluent B.
The ow rate was set to 1.0 mL min1 and an injection volume
of 10 mL was applied. The chromatographic separation was
carried out at room temperature while detecting the target
compounds at a wavelength of 278 nm.
HPLC-ICP-MS/MS. A baseline separation of the target deriv-
atives from the interfering matrix components and from each
other could be achieved on a Waters Acquity UPLC BEH C18
column (2.1  100 mm, 1.7 mm) using the same HPLC system
mentioned in the previous section. Gradient elution was
applied at room temperature at a ow rate of 0.4 mL min1 as
follows: 0–25 min: 50/ 0% eluent A (50/ 100% eluent B); 25–
27 min: 0% eluent A (100% eluent B). Between 27–32 min the
column was reconditioned with a 50 : 50 (v/v) eluent A–eluent B
mixture. The injection volume was set to 10 mL. An Agilent 1290
Innity series 2 position/10 port microvalve was applied to avoid
the contamination of the ICP-MS system caused by the large
amount of excess reagent by directing the HPLC eﬄuent as
follows: 0–8 min: to waste; 8–32 min: to ICP-MS/MS unit.
For the element-selective detection, an Agilent 8800 “triple
quadrupole” ICP-MS/MS instrument (ICP-QQQ, Agilent Tech-
nologies, Tokyo, Japan) equipped with two quadrupole mass
analyzers (Q1 and Q2) and an octopole collision/reaction cell
mounted in-between the 2 analyzers was used. In order to
reduce the organic load of the plasma, a low internal volume
PFA-LC nebulizer (Elemental Scientic, Omaha, NE, USA) tted
onto a Peltier-cooled Scott-type spray chamber and a torch with
a 1.0 mm internal diameter injector tube (Agilent Technologies,
Tokyo, Japan) were applied for the sample introduction. 20% (v/
v) O2 in Ar (option gas) was admixed to the carrier gas ow to
prevent carbon build-up on the torch and cones. Both the
sampler and skimmer cones were made of Pt instead of the
generally applied Ni, which is less resistant to the corrosive
environment caused by the use of O2. For the simultaneous
determination of Cl and Br, an ICP-MS/MS approach recently
published by Klencsa´r et al. was applied.36 Briey, H2 was used
as a reaction gas to ensure an interference-free determination of
both elements. While Cl was determined as 35Cl1H2
+ employing
amass shi of 2 amu between the two quadrupole analyzers (Q2
¼Q1 + 2), Br could be determined on-mass atm/z¼ 79. Detailed
operating parameters of the ICP-MS/MS instrument are listed in
Table 1.
HPLC-ESI-MS. An Agilent 1100 HPLC system (Agilent Tech-
nologies, Waldbronn, Germany) coupled to a Thermo-Finnigan
LCQ Deca XP Plus mass spectrometer (Thermo Fisher Scientic,This journal is © The Royal Society of Chemistry 2018
Table 1 ICP-MS/MS operating conditions
Parameters Setting
RF power 1550 W
Carrier gas ow rate 0.33 L min1
H2 gas ow rate 3.5 mL min
1
Optional gas (20% O2 in Ar) 20%
Temperature of spray chamber 1 C
Monitored transitions/masses Q1: m/z 35 (Cl+)/ Q2: m/z 37
(ClH2
+), Q1: m/z 79 (Br+)/ Q2:
m/z 79 (Br +)
Data collection mode TRA (transient signal mode)
Energy discrimination setting 3.5 V
Integration time 0.3 s for m/z 37, 0.1 s for m/z 79
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View Article OnlineWaltham, MA, USA) was used to conrm the structure of the
derivatized products of diclofenac and 40-hydroxy-diclofenac.
The derivatives were separated on a Waters XBridge Phenyl
column (3.0 150 mm, 3.5 mm) with a mobile phase ow rate of
0.5 mL min1. A gradient elution program with eluent A (0.05%
(v/v) formic acid in MQ water) and eluent B (0.05% (v/v) formic
acid in acetonitrile) was employed as follows: 0–25 min: 50/
0% eluent A (50 / 100% eluent B), 25–27 min: 0% eluent A
(100% eluent B). The mass spectrometer was operated in posi-
tive electrospray ionization (ESI+) mode with the following
operating conditions: acquisition range: m/z 100–800, sheath
gas ow rate: 60 arb, aux gas ow rate: 20 arb, spray voltage: 4.0
kV, capillary temperature: 300 C and capillary voltage: 4.0 V.
Results and discussion
Optimization of the derivatization procedure
p-BPB is a well-known alkylating agent for carboxylic acids,
applied to improve their UV detectability. As mentioned above,Table 2 Optimization of the reaction conditions: peak area units of the
derivatives obtained by using HPLC-UV at a detection wavelength of 27
Factors Values
Peak area units
Diclofenac
40-Hydroxy-
diclofenac
TEA concentration 2 mM <LOQ <LOQ
4 mM <LOQ <LOQ
10 mM <LOQ <LOQ
20 mM <LOQ <LOQ
Reaction temperature RT <LOQ 6.6
40 C <LOQ <LOQ
60 C <LOQ <LOQ
80 C <LOQ <LOQ
Reaction time 15 min <LOQ <LOQ
30 min <LOQ <LOQ
45 min <LOQ <LOQ
60 min <LOQ <LOQ
p-BPB concentration 4 mM <LOQ <LOQ
8 mM <LOQ <LOQ
20 mM <LOQ <LOQ
40 mM <LOQ <LOQ
a LOQ is 0.1 mM for both diclofenac and 40-hydroxy-diclofenac which is cor
conditions.
This journal is © The Royal Society of Chemistry 2018besides the benets related to UV-absorbance, the introduction
of Br into the target compounds enables element-selective
detection with ICP-MS/MS. In the present study, diclofenac
and its major metabolite 40-hydroxy-diclofenac were derivatized
in human plasma matrix, as demonstrated in Fig. 1. To ensure
a quantitative conversion of both target compounds in such
a heavy matrix as human plasma, the reaction conditions were
carefully optimized by using spiked plasma samples prepared
via the reconstitution of dry plasma extracts in 200 mL aceto-
nitrile, containing 100 mM of diclofenac and 100 mM of 40-
hydroxy-diclofenac. The inuence of the concentration of TEA,
of the reaction temperature, of the reaction time and of the
concentration of the reagent were systematically evaluated. The
reaction eﬃciency was studied by applying an HPLC-UVmethod
(as detailed in the Experimental section) for monitoring the
peak areas of the starting compounds (diclofenac and 40-
hydroxy-diclofenac) and their derivatives.
The concentration of TEA was investigated in a concentra-
tion range of 0.5–5 mM in the nal reaction mixture as follows.
200 mL of spiked plasma sample (prepared from the recon-
stituted plasma samples and resulting in 50 mM of diclofenac
and 50 mM of 40-hydroxy-diclofenac in the nal reaction
mixture) was mixed with 100 mL of 40 mM p-BPB solution
(resulting in 10 mM p-BPB in the nal reactionmixture) and 100
mL of TEA solution with a concentration range of 2 to 20 mM.
The reaction was performed at 80 C for 60 minutes. No residue
of the starting compounds (diclofenac and 40-hydroxy-
diclofenac) was observed independent of the TEA concentra-
tion, as can be seen from Table 2. However, two derivatization
products were observed for 40-hydroxy-diclofenac due to the
presence and partial conversion of a phenolic –OH group in its
chemical structure, as can be seen in Fig. S-1 in the ESI† and
from Table 2. The reactivity of a phenolic –OH group isstarting compounds (diclofenac and 40-hydroxy-diclofenac) and their
8 nma
Derivative of
diclofenac
Primary derivative
of 40-hydroxy-diclofenac
Secondary derivative
of 40-hydroxy-diclofenac
121.8 16.4 91.8
121.5 13.0 97.8
125.9 4.8 104.3
127.4 1.5 108.7
105.7 12.5 96.5
119.7 9.3 101.5
125.1 3.4 104.2
127.1 1.3 107.2
121.4 4.9 101.5
123.5 2.9 104.3
127.3 1.5 108.7
127.1 1.3 107.2
114.5 37.3 51.1
116.6 21.2 79.6
123.3 7.3 101.8
127.4 1.5 108.7
responding to >99% conversion for the two compounds in these reaction
J. Anal. At. Spectrom., 2018, 33, 274–282 | 277
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View Article Onlineobviously much lower due to its weaker acidity compared to that
of a carboxyl group. The application of a 20 mM TEA solution
was necessary to achieve a near-to 100% conversion of 40-
hydroxy-diclofenac into its secondary derivative.
To achieve a complete conversion of the target compounds
into single derivatives, the eﬀects of reaction temperature and
time were also investigated. 100 mL of 20 mM TEA solution
(resulting in 5 mMTEA in the nal reactionmixture) and 100 mL
of 40 mM p-BPB solution (resulting in 10 mM p-BPB in the nal
reaction mixture) were added to 200 mL of spiked plasma
sample (with 50 mM of both diclofenac and 40-hydroxy-
diclofenac in the nal reaction mixture) and the mixture was
kept at room temperature (20–24 C), 40, 60 and 80 C for 60
minutes. While diclofenac was completely converted into its
derivative regardless of the temperature applied, a near-to 100%
conversion of the phenolic –OH of 40-hydroxy-diclofenac could
be achieved at 80 C only, due to its weaker acidity (thus lower
reactivity) compared to that of the carboxyl group, as demon-
strated in Table 2 and Fig. S-2 in the ESI.† As mentioned above,
the eﬀect of reaction time was also studied by allowing the
reaction to proceed for 15, 30, 45 and 60 minutes at 80 C
following the procedure detailed above. As can be seen from theFig. 2 ESI-MS spectrum of the protonated ion [M + H]+ and isotope distr
diclofenac (B).
278 | J. Anal. At. Spectrom., 2018, 33, 274–282results presented in Table 2 and Fig. S-3 in the ESI,† a duration
of 45 minutes was satisfactory for quantitative conversion into
the targeted derivatives.
The eﬀect of reagent concentration was also evaluated in
a range of 4–40 mM (corresponding to 1–10 mM p-BPB in the
nal reaction mixture) to guarantee a full conversion of the
target analytes into single derivatives. 100 mL of p-BPB solution
and 100 mL of 20 mM TEA solution (resulting in 5 mM TEA in
the nal reaction mixture) were added to 200 mL of recon-
stituted plasma sample (spiked with 50 mM of both diclofenac
and 40-hydroxy-diclofenac in the nal reaction mixture)
followed by the reaction carried out under the optimal
conditions detailed above. As presented in Table 2 and Fig. S-4
in the ESI,† 40 mM of p-BPB was needed to achieve a near-to
100% conversion of diclofenac and 40-hydroxy-diclofenac
into their target derivatives. Reviewing the peak area results
in Table 2, it can be concluded that relatively mild conditions
are satisfactory for the quantitative derivatization of a carboxyl
group even in such a heavy biological matrix as human
plasma. However, due to its weaker acidity, the phenolic –OH
function requires harsher circumstances regarding all
parameters investigated.ibution of the derivatization products of diclofenac (A) and 40-hydroxy-
This journal is © The Royal Society of Chemistry 2018
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View Article OnlineStructural identication of the derivatization products
The structural identication of derivatization products was
performed by HPLC-ESI-MS, as detailed in the Experimental
part. The HPLCmethod was slightly modied compared to that
applied for HPLC-ICP-MS/MS purposes to improve its
compatibility with the HPLC-ESI-MS system employed. The
acidic eluent additive 0.05% (v/v) triuoroacetic acid was
replaced by 0.05% (v/v) formic acid to avoid the strong signal
suppression eﬀect exerted by the former. Also a diﬀerent (3.0 
150 mm; 3.5 mm) HPLC column was applied instead of a sub-2-
micron column to allow HPLC-ESI-MS at conventional pres-
sure. Nevertheless, the separation observed with this slightly
modied set-up allowed structural identication. As demon-
strated in Fig. 2, the isotope distributions observed (black
lines) are in good agreement with the theoretical values (orange
bars) for the molecular ions [M + H]+ of both derivatives.
Therefore, the results conrmed the expected structures of the
derivatives of both diclofenac and 40-hydroxy-diclofenac (pre-
sented in Fig. 1).Fig. 3 Selectivity of the HPLC-ICP-MS/MS method: (A) chlorine
chromatograms for derivatized blank plasma (blue) and derivatized
spiked plasma sample (red), (B) bromine chromatograms for derivat-
ized blank plasma (grey) and derivatized spiked plasma sample
(green)1. Peaks: 1: the derivative of diclofenac; 2: the secondary
derivative of 40-hydroxy-diclofenac. 1The ﬁrst 8 minutes part of the
chromatographic runs is directed into the waste as detailed in the
Instrumentation section.Chromatographic method development for HPLC-ICP-MS/MS
In case of the application of chemical derivatization for HPLC-
ICP-MS(/MS) determination of drugs and drug-related
compounds in biological matrices, the development of a suit-
able chromatographic method for the separation of the deriv-
atization products from the interfering matrix and from each
other is one of the most challenging steps due to the high
complexity of the derivatized sample. As mentioned previously,
a large excess of derivatization reagent must be added to ensure
a suﬃcient conversion eﬃciency of the target analytes during
derivatization in the presence of such a heavy matrix as human
plasma due to the fact that the most common functional groups
of pharmaceuticals are also extensively present in biological
matrices. Although a simple HPLC-UV method could be applied
for the optimization of the reaction conditions (as detailed
above), the separation of the targeted derivatization products
suﬀered frommatrix-related interferences. Thus, for the sake of
an accurate quantication using HPLC-ICP-MS/MS, a separate
chromatographic method was developed focusing on the
baseline separation of the targeted derivatization products
(derivative of diclofenac and second order derivative of 40-
hydroxy-diclofenac) from the interfering matrix components.
Several columns including an Agilent Poroshell 120 EC-C18 (3.0
 50 mm, 2.7 mm), a Waters SunFire C18 (4.6  150 mm, 3.5
mm), a Waters XBridge BEH C18 (4.6  150 mm, 3.5 mm),
a Waters XBridge BEH Phenyl (3.0  150 mm, 3.5 mm) and
a Waters Acquity UPLC BEH C18 (2.1  100 mm, 1.7 mm) were
tested with diﬀerent eluent systems, such as 10mM ammonium
acetate buﬀer (pH ¼ 5.7), 0.05% (v/v) triuoroacetic acid and
0.05% (v/v) formic acid in MQ water and acetonitrile. Finally,
the optimum separation was achieved by using aWaters Acquity
UPLC BEH C18 (2.1  100 mm, 1.7 mm) column with an eluent
system consisting of 0.05% (v/v) TFA in MQ water and 0.05% (v/
v) TFA in acetonitrile, applying gradient elution as detailed in
the Experimental section.This journal is © The Royal Society of Chemistry 2018Quantication strategy for HPLC-ICP-MS analysis
The continuously changing eluent composition (as a result of
the application of gradient elution) may be a major issue
during quantication in HPLC-ICP-MS due to the continu-
ously changing composition of the sample injected into the
ICP and thus, the continuously changing sensitivity.37 There-
fore, this eﬀect was also tested for the optimal HPLC method
to ensure accurate quantication of the target compounds.
Based on the retention time of the target compounds, the void
time and the gradient delay volume of the HPLC system, the
exact solvent compositions corresponding to each peak could
be easily calculated. Due to the relatively close retention times
of the two derivatives (12.0  0.1 min for the diclofenac
derivative and 14.9  0.1 min for the 40-hydroxy-diclofenac
derivative), less than 6% diﬀerence in the acetonitrile
content was observed between the two peak positions. To
investigate the possible eﬀect of this diﬀerence, a ow injec-
tion study was performed, based on multiple injections (n ¼ 6)
of Cl and Br (5 mg L1 Cl as diclofenac and 0.5 mg L1 Br as
NH4Br) standard solutions in both eluent compositions – 73%
(v/v) and 79% (v/v) acetonitrile in MQ water, corresponding toJ. Anal. At. Spectrom., 2018, 33, 274–282 | 279
Table 3 Results of linearity study
Calibration
approach Parameter Br Cl
External
standard
Equation of
calibration
curve
y ¼ 1708700x
 26 400
y ¼ 77900x + 3600
R2 0.9999 0.9998
95% condence
interval
of intercept
72 500 5600
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View Article Onlinethe elution positions of the derivatives of diclofenac and 40-
hydroxy-diclofenac, respectively – aiming at the determination
of the ICP-MS/MS response for both elements in both solvent
compositions. A t-test at 5% signicance level was applied to
compare the two sets of sensitivity data for both elements,
demonstrating that the bias deriving from the diﬀerence of the
eluent composition observed in this specic case is negligible.
Therefore, a simple 5-point external standard calibration
approach, based on the injection of a set of standard solutions
in a concentration range of 0.1–6.0 mg L1 for both elements
(Br as NH4Br and Cl as diclofenac) dissolved in 75% (v/v)
acetonitrile (containing 0.05% (v/v) TFA) could be further
applied for quantication purposes, while maintaining an
isocratic ow of 25% (v/v) eluent A (75% (v/v) eluent B) at a ow
rate of 0.4 mLmin1. Due to the fast elution of diclofenac (tR¼
1.0 min) under these conditions, the removal of the analytical
column (Waters Acquity UPLC BEH C18) applied for the
separation of the target compounds in the derivatized samples
was not necessary at the time of calibration either, simplifying
the analytical sequence.Method validation
The method validation was performed according to the ICH
Q2(R1) guideline (Validation of Analytical Procedures: Text and
Methodology) in terms of selectivity, linearity, limit of quanti-
cation (LOQ), accuracy and precision.38 The presence of both
Br and Cl in the derivatives, allowed for an additional evaluation
of the accuracy and precision realized with the novel approach.Table 4 Accuracy and precision of the results obtained for diclofenac a
quent HPLC-ICP-MS/MS analysis
Target analytes
Cl
Concentration level (mg L1 Cl)
Recovery
(%)
Diclofenac 0.1 103.3
0.4 93.5
0.8 93.1
40-Hydroxy-diclofenac 0.1 100.6
0.4 88.5
0.8 87.0
280 | J. Anal. At. Spectrom., 2018, 33, 274–282The selectivity was evaluated by comparing the chromato-
grams of the derivatized blank plasma sample and blank
human plasma sample spiked with 0.8 mg L1 Cl as diclofenac
and 0.8 mg L1 Cl as 40-hydroxy-diclofenac, resulting in
0.9 mg L1 Br as the derivative of diclofenac and 1.8 mg L1 Br
as the derivative of 40-hydroxy-diclofenac in the nal sample. As
shown in Fig. 3, no interfering peaks were observed in the
chromatograms of the blank human plasma at the peak posi-
tions of the target compounds for both Br and Cl.
The linearity was evaluated by injecting Br (as NH4Br) and Cl
(as diclofenac) mixed standard solutions dissolved in 75% (v/v)
acetonitrile (containing 0.05% (v/v) TFA) at ve diﬀerent
concentration levels covering the range of 0.1–6 mg L1 for both
elements while maintaining an isocratic ow of 25% (v/v) eluent
A (75% (v/v) eluent B) at a ow rate of 0.4 mL min1. The
equation for the calibration curves, the correlation coeﬃcients
and the 95% condence interval of the intercepts are presented
in Table 3. An excellent linearity with R2 > 0.99 was obtained for
both Br and Cl; furthermore, the 95% condence interval of the
intercept involves origo in both cases.
The LOQ was determined as the concentration where
a signal-to-noise ratio (S/N) of 10 : 1 was obtained for the cor-
responding peak. The S/N was determined according to USP
h621i. The LOQ values determined based on the peak of the
diclofenac-derivative for both elements werez50 mg L1 for Br
and z80 mg L1 for Cl, corresponding to z0.2 mg L1 and
z0.4 mg L1 of diclofenac, respectively, in the nal sample
solution. These values are in good agreement with those pub-
lished in the literature so far.12,16,18,28,36,37,39,40
Accuracy and precision were assessed by analyzing spiked
plasma samples at three concentration levels with three repli-
cate sample preparations at each level in the range of 0.1–0.8 mg
mL1 of Cl as diclofenac and 40-hydroxy-diclofenac, corre-
sponding to 0.1–0.9 mg mL1 and 0.2–1.8 mg mL1 of Br,
respectively, in the nal sample solution injected into the
HPLC-ICP-MS/MS system. The results for accuracy and preci-
sion are summarized in Table 4. As can be seen, the recovery is
between 85 and 115% at each level, accompanied by a precision
#7.2 RSD%. Hence, the new approach is considered suﬃciently
precise and accurate. Furthermore, good agreement was also
found between the results obtained based on Cl- and Br-
detection.nd 40-hydroxy-diclofenac after pre-column derivatization and subse-
Br
Precision
(RSD%)
Concentration level
(mg L1 Br)
Recovery
(%)
Precision
(RSD%)
2.7 0.1 99.2 6.2
1.5 0.5 92.1 1.9
0.4 0.9 93.6 2.3
5.2 0.2 96.0 6.6
2.9 0.9 86.6 7.2
4.0 1.8 84.5 2.8
This journal is © The Royal Society of Chemistry 2018
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View Article OnlineConclusions
In this work, pre-column derivatization of a carboxyl group
containing pharmaceutical (diclofenac) followed by HPLC-ICP-
MS/MS determination was successfully used for the purpose
of quantitative metabolite proling. A simple and inexpensive
alkylation reagent, p-bromophenacyl bromide was applied for
the derivatization of the carboxyl- and phenolic –OH groups
present in the molecules of diclofenac and its major metabolite,
40-hydroxy-diclofenac, in the presence of human plasma matrix.
The combination of chemical derivatization and HPLC-ICP-
MS(/MS) can overcome the typical absence of ICP-MS acces-
sible elements in active pharmaceutical ingredients (APIs), thus
enabling accurate quantication of specic metabolites in the
absence of authentic standards, and thus oﬀering a sterling
alternative to radio-HPLC in some cases. The novel approach
provided suﬃcient sensitivity, accuracy and precision. Although
the LOQ obtained for these specic target compounds (diclo-
fenac and 40-hydroxy-diclofenac) is exceeding that achievable by
using LC-MS,41,42 it must be emphasized that LC-ICP-MS(/MS) is
not intended to be an alternative technique for LC-MS. LC-MS is
the method of choice for metabolite identication, but as for
reliable quantication, it requires an individual standard for
each analyte of interest, it is less suited for determination of the
quantities of the metabolites produced. It is exactly for this
purpose that LC-ICP-MS(/MS) is suggested in this paper. It
should also be noted that the present derivatization method-
ology may be also applicable to other biological sample types
(e.g., urine and faeces) commonly analyzed in the context of
metabolite proling studies, but the re-optimization of the
derivatization conditions could be required depending on the
sample type (presence of endogenic compounds interacting
with the derivatization reagent).
So far, in our work on metabolite proling using HPLC-ICP-
MS(/MS), a derivatization approach for three of the most
abundant functional groups in pharmaceuticals, i.e. primary
amino groups (in a former work28) and carboxyl and phenolic
–OH groups in the present study was presented. To introduce
this approach as a routine tool in pharmaceutical R&D, further
research within this eld is required and a similar derivatiza-
tion reagent database to those that already exist for, e.g., GC
analysis of non-volatile compounds or HPLC-UV/uorescence
analysis of amino acids, would need to be established for ICP-
MS(/MS) as well.
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